Cargando…
Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice
Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells...
Autores principales: | Kang, Hwa Jeong, Kim, Jeehye, Cho, Seong Hyeok, Park, So-Jung, Yoo, Hwa-Seung, Kang, In-Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419252/ https://www.ncbi.nlm.nih.gov/pubmed/30866688 http://dx.doi.org/10.1177/1534735419830765 |
Ejemplares similares
-
Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype
por: Park, Hye-Rin, et al.
Publicado: (2017) -
Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib
Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022) -
Prospective Analysis on Survival Outcomes of Nonsmall Cell Lung Cancer Stages over Ⅲb Treated with HangAm-Dan
por: JEONG, Tae-Young, et al.
Publicado: (2010) -
A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
por: Song, Si-Yeon, et al.
Publicado: (2020) -
Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
por: Song, Si-Yeon, et al.
Publicado: (2021)